Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
Akintunde Akinleye, Parthu Avvaru, Muhammad Furqan, et al.
Journal of Hematology & Oncology (2013) Vol. 6, Iss. 1
Open Access | Times Cited: 239

Showing 1-25 of 239 citing articles:

Kinase-targeted cancer therapies: progress, challenges and future directions
Khushwant S. Bhullar, Naiara Orrego Lagarón, Eileen McGowan, et al.
Molecular Cancer (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 1052
Targeting PI3K/Akt signal transduction for cancer therapy
Yan He, Miao Sun, Guo Geng Zhang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 890
PROTACs: great opportunities for academia and industry
Xiuyun Sun, Hongying Gao, Yiqing Yang, et al.
Signal Transduction and Targeted Therapy (2019) Vol. 4, Iss. 1
Open Access | Times Cited: 508
The relation between PI3K/AKT signalling pathway and cancer
Saeed Noorolyai, Neda Shajari, Elham Baghbani, et al.
Gene (2019) Vol. 698, pp. 120-128
Closed Access | Times Cited: 495
PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux
Jake S. O’Donnell, Daniela Massi, Michele W.L. Teng, et al.
Seminars in Cancer Biology (2017) Vol. 48, pp. 91-103
Open Access | Times Cited: 321
Anti-Inflammatory Drugs as Anticancer Agents
Silvia Zappavigna, Alessia Maria Cossu, Anna Grimaldi, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 7, pp. 2605-2605
Open Access | Times Cited: 297
Breast Cancer Treatments: Updates and New Challenges
Anna Burguin, Caroline Diorio, Francine Durocher
Journal of Personalized Medicine (2021) Vol. 11, Iss. 8, pp. 808-808
Open Access | Times Cited: 275
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
Shundong Cang, Chaitanya Iragavarapu, John Savooji, et al.
Journal of Hematology & Oncology (2015) Vol. 8, Iss. 1
Open Access | Times Cited: 257
Immunological Approaches Towards Cancer and Inflammation: A Cross Talk
Xinglong Qu, Ying Tang, Shucheng Hua
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 257
Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathway
Qiaofen Fu, Yan Liu, Yue Fan, et al.
Journal of Hematology & Oncology (2015) Vol. 8, Iss. 1
Open Access | Times Cited: 235
Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies
Kim M. Keppler‐Noreuil, Victoria Parker, Thomas N. Darling, et al.
American Journal of Medical Genetics Part C Seminars in Medical Genetics (2016) Vol. 172, Iss. 4, pp. 402-421
Open Access | Times Cited: 232
Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients
Filip Janků
Cancer Treatment Reviews (2017) Vol. 59, pp. 93-101
Open Access | Times Cited: 212
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
Rosalin Mishra, Hima Patel, Samar Alanazi, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 7, pp. 3464-3464
Open Access | Times Cited: 198
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
Nicholas C. Turner, Patrick Neven, Sibylle Loibl, et al.
The Lancet (2016) Vol. 389, Iss. 10087, pp. 2403-2414
Closed Access | Times Cited: 183
Long non-coding RNA-SNHG7 acts as a target of miR-34a to increase GALNT7 level and regulate PI3K/Akt/mTOR pathway in colorectal cancer progression
Yang Li, Zeng Chang-qian, Jialei Hu, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 182
Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
Qingfang Li, Zhihui Li, Ting Luo, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 116
Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy
Marianna Sirico, Alberto D’Angelo, Caterina Gianni, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 703-703
Open Access | Times Cited: 55
Targeting Breast Cancer: An Overlook on Current Strategies
Domenico Iacopetta, Jessica Ceramella, Noemi Baldino, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3643-3643
Open Access | Times Cited: 44
Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer
Carla L. Alves, Henrik J. Ditzel
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4522-4522
Open Access | Times Cited: 42
PI3K–AKT-Targeting Breast Cancer Treatments: Natural Products and Synthetic Compounds
Yeqin Yuan, Hui‐Zhi Long, Ziwei Zhou, et al.
Biomolecules (2023) Vol. 13, Iss. 1, pp. 93-93
Open Access | Times Cited: 41
Differential regulatory functions of three classes of phosphatidylinositol and phosphoinositide 3-kinases in autophagy
Xinlei Yu, Yun Chau Long, Han‐Ming Shen
Autophagy (2015) Vol. 11, Iss. 10, pp. 1711-1728
Open Access | Times Cited: 176
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial
Anas Younes, Jesús G. Berdeja, Manish R. Patel, et al.
The Lancet Oncology (2016) Vol. 17, Iss. 5, pp. 622-631
Open Access | Times Cited: 165
Update on Head and Neck Cancer: Current Knowledge on Epidemiology, Risk Factors, Molecular Features and Novel Therapies
Francesca Pezzuto, Luigi Buonaguro, Francesco Caponigro, et al.
Oncology (2015) Vol. 89, Iss. 3, pp. 125-136
Closed Access | Times Cited: 163
Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
Jingjing Wu, Jiaping Fu, Mingzhi Zhang, et al.
Journal of Hematology & Oncology (2015) Vol. 8, Iss. 1
Open Access | Times Cited: 146
LAMB3 mediates apoptotic, proliferative, invasive, and metastatic behaviors in pancreatic cancer by regulating the PI3K/Akt signaling pathway
Hong Zhang, Yaozhen Pan, May Cheung, et al.
Cell Death and Disease (2019) Vol. 10, Iss. 3
Open Access | Times Cited: 142
Page 1 - Next Page

Scroll to top